Original reporting and analysis on the stories shaping biotech.
An arbitration panel just ruled that Prime Medicine didn't violate its agreement with Beam Therapeutics by developing a rare disease therapy, clearing the way for Prime to enter the clinic. The ruling sends a sharp signal about how gene-editing IP disputes will be settled going forward.
For decades, CAR-T therapy has crashed and burned against solid tumors. Allogene's off-the-shelf ALLO-316 just posted durable remissions in advanced kidney cancer that are still going past 18 months, and Wall Street is paying attention.
Two of 2026's largest biotech venture rounds landed on back-to-back days: $400 million for AI drug designer Chai Discovery and $315 million for radiopharmaceutical developer AdvanCell. The $715 million blitz reveals exactly where smart money thinks the future of drug development is headed.
GSK walked away from a $2.2 billion neuroscience deal with Alector after both antibody drugs flopped in clinical trials. The $700 million already spent is gone, and the wreckage says a lot about why brain diseases remain pharma's hardest problem.
Europe just greenlit the world's first combined flu-COVID vaccine, and it's not just a convenience play. Moderna's mCOMBRIAX could reshape seasonal vaccination, plug a dangerous coverage gap in older adults, and throw the company a financial lifeline it desperately needs.
AstraZeneca just dropped $200 million upfront for a Chinese-made COPD drug you've probably never heard of, with up to $1.9 billion more on the table. The deal says as much about China's biotech boom as it does about the race to dominate respiratory medicine.
Gilead Sciences is paying up to $5 billion for Tubulis, a German ADC startup most people have never heard of. The deal signals that big pharma's antibody-drug conjugate arms race just entered a new, much more expensive phase.
Merck KGaA is spending $11.3 billion in cash to acquire Bio-Techne, a company most people outside the lab have never heard of. The deal is the largest life sciences tools acquisition of 2026 and a bold bet that owning the picks and shovels of drug discovery is just as valuable as the drugs themselves.
Congress is investigating why Merck and AbbVie ran hundreds of clinical trials at Chinese military hospitals and in Xinjiang, raising national security and human rights concerns that could reshape how Big Pharma develops drugs globally.
For over two years, no gene-editing company dared to go public. Scribe Therapeutics just priced a $129 million IPO at the top of its range, with Sanofi buying in alongside public investors. The gene-editing IPO drought is officially over.
Two biotech startups claim they've grown human sperm from testicular stem cells and created early egg cells from a simple blood draw. If the science holds up, the future of human reproduction just got a radical rewrite.
Europe's drug regulator just recommended revoking Amgen's Tavneos after investigators found the clinical trial that got it approved was built on manipulated data. The case is a $3.7 billion cautionary tale with implications for every biotech acquirer, investor, and drug developer in the industry.
Otsuka's centanafadine just hit its FDA decision deadline, and the silence is deafening. The first triple-reuptake inhibitor for ADHD could reshape a $15 billion market, if the agency says yes.
Genentech cut 103 research scientists the same week it signed a $490 million breast cancer deal with Astex Pharmaceuticals. It's the starkest example yet of big pharma's new playbook: shrink internally, shop externally.
A tiny trial at Dana-Farber just showed that a single CAR-T infusion wiped out detectable disease in every patient with high-risk smoldering myeloma, and none have progressed to cancer. It's only 20 patients, but the implications are massive.
The FDA just built a regulatory highway for gene therapies designed for as few as one patient. It could transform rare disease treatment, but the economics are genuinely terrifying.
AstraZeneca and Ionis's eplontersen just failed the largest ATTR cardiomyopathy trial ever run, despite crushing it in nerve disease. The surprise flop reshuffles a multi-billion-dollar market and hands a massive gift to Alnylam and BridgeBio.
Eli Lilly's retatrutide just posted the best weight-loss numbers any drug has ever achieved, rivaling bariatric surgery. But its failure to show a clear cardiovascular benefit could limit insurance coverage and hand competitors a surprising edge.
Small cell lung cancer has defeated almost every new drug for decades. GSK and Hansoh's ADC just became the first B7-H3 therapy to show a survival benefit in a phase III trial, and it could reshape one of oncology's most stubborn battlegrounds.
Sarepta slapped the FDA's most severe safety warning on its gene therapy Elevidys after patient deaths, then cut 500 workers in the same week. With the stock down 80% and $1 billion in debt looming, the leading Duchenne muscular dystrophy company is fighting for survival.
For over a decade, CAR-T therapy dominated blood cancers but couldn't crack solid tumors. China just approved the world's first solid-tumor CAR-T for stomach cancer, and the implications for the entire cell therapy field are enormous.
Novartis is paying $1.1 billion upfront for Myricx Bio, a London biotech with zero approved drugs and a completely novel ADC payload nobody else is using. It's either a visionary platform play or the most expensive preclinical bet in pharma history.
Join thousands of biotech professionals who start their day with our free, daily briefing.